PML and ovarian cancer: The combination of cisplatin and the mTOR inhibitor GALNT14 had a cumulative effect by promoting apoptosis and ferroptosis of ovarian cancer cells, which may offer a new target for overcoming cisplatin resistance in ovarian cancer (103).By increasing ROS, lipid peroxidation, and iron homeostasis in high-OXPHOS high-grade serous ovarian cancer (HGSOC), the promyelocytic leukemia protein-peroxisome proliferator-activated receptor gamma coactivator-1a (PML-PGC-1a) axis can help make ovarian cancer more sensitive to chemotherapy.